NCT02031289View on ClinicalTrials.gov

Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome.

PHASE4CompletedINTERVENTIONAL
Enrollment

1,003

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

May 31, 2018

Conditions
AnemiaIron Deficiency
Interventions
DRUG

Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid

"Treatment ) will be given the day before the operation (day -1) or a maximum of 2 days prior to the operation (day -2) in iron deficiency patients and a maximum of 3 days prior to the operation in anemic patients (day -3).~Erythropoietin alpha (Eprex, Janssen-Cilag AG, Baar) 40'000 U sc. Ferric carboxymaltose (Ferinject, Vifor (International) AG, St. Gallen) 1000 mg in 100 ml NaCl over 30 min.~Vitamin B12 (Vitarubin®-superconc., Streuli Pharma AG, Uznach) 1 mg sc. Folic acid (Acidum folicum, Streuli Pharma AG, Uznach) 5 mg po."

Trial Locations (1)

8091

University Hospital Zurich, Institute of Anaesthesiology, Zurich

All Listed Sponsors
lead

University of Zurich

OTHER

NCT02031289 - Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome. | Biotech Hunter | Biotech Hunter